Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 5/20 | 0.34 |
| ▸ | TDP2 | O95551 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 2/20 | 0.31 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804096 | 0.85 | KIF11 (0.43) | EIF4A3KIF11 | |
| SCHEMBL13052359 | 0.81 | GRIA1 (0.41) | GRIA1CACNG8MEN1KMT2AAHR | |
| SCHEMBL25153990 | 0.80 | EIF4A3 (0.33) | EIF4A3 | |
| SCHEMBL5498437 | 0.77 | GRIA1 (0.41) | GRIA1CACNG8AHRTDP2CMA1 | |
| SCHEMBL1318667 | 0.77 | TGM2 (0.44) | GRIA1CACNG8AHRTDP2CMA1 | |
| SCHEMBL12430394 | 0.76 | MALT1 (0.35) | MEN1KMT2AAHRTDP2HPGD | |
| SCHEMBL14334081 | 0.76 | GRIA1 (0.39) | GRIA1CACNG8AHRTDP2CACNG2 | |
| SCHEMBL1163094 | 0.74 | GRIA1 (0.41) | GRIA1CACNG8AHRTDP2CMA1 | |
| SCHEMBL4297627 | 0.74 | TDP2 (0.46) | GRIA1CACNG8MEN1KMT2AAHR | |
| SCHEMBL20112858 | 0.74 | TDP2 (0.46) | GRIA1CACNG8AHRTDP2CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | GRIA1 1284/4885CACNG8 355/4885MEN1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.